The allelic composition of an individual's apolipoprotein (ApoE) can significantly impact the risk of developing Alzheimer's disease.
Image Credit: Molecular Devices
People with two copies of the E4 allele (ApoE4/4) have a ~65% chance of developing Alzheimer's disease (AD) by age 85, compared to only 10% in people with both wild-type E3 alleles.
This remarkable difference establishes ApoE4 as a significant genetic risk factor for Alzheimer's disease and emphasizes its role in disease pathogenesis.
This app note shows how to replicate Alzheimer's disease in iPSC-derived neurons modified with ApoE allelic variations (E2/2, E3/3, and E4/4).
This biological system of 3D neurospheres and a detailed examination of calcium oscillations offer a potential and informative tool for disease modeling and phenotypic functional evaluation, which can be applied to compound testing.
Download the App Note
About Molecular Devices UK Ltd 
Molecular Devices is one of the world’s leading providers of high-performance life science technology. We make advanced scientific discovery possible for academia, pharma, and biotech customers with platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. From cancer to COVID-19, we've contributed to scientific breakthroughs described in over 230,000 peer-reviewed publications.
Over 160,000 of our innovative solutions are incorporated into laboratories worldwide, enabling scientists to improve productivity and effectiveness – ultimately accelerating research and the development of new therapeutics. Molecular Devices is headquartered in Silicon Valley, Calif., with best-in-class teams around the globe. Over 1,000 associates are guided by our diverse leadership team and female president that prioritize a culture of collaboration, engagement, diversity, and inclusion.
To learn more about how Molecular Devices helps fast-track scientific discovery, visit www.moleculardevices.com.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.